Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25974304 | 0.90 | CYP4F2 (0.35) | CYP4F2CYP4A11GABRA2GABRB2 | |
| SCHEMBL25751753 | 0.82 | RXRA (0.35) | — | |
| SCHEMBL14900340 | 0.80 | GABRA2 (0.34) | CYP4F2CYP4A11GABRA2GABRB2 | |
| SCHEMBL14212090 | 0.80 | GABRA2 (0.38) | CYP4F2CYP4A11GABRA2GABRB2 | |
| SCHEMBL14900333 | 0.79 | CYP4F2 (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL15222209 | 0.78 | GABRA2 (0.45) | GABRA2GABRB2 | |
| SCHEMBL16216284 | 0.78 | GABRA2 (0.33) | CYP4F2CYP4A11GABRA2GABRB2 | |
| SCHEMBL25588830 | 0.77 | DDX3X (0.41) | CYP4F2CYP4A11GABRA2GABRB2 | |
| SCHEMBL14212094 | 0.77 | NOTUM (0.41) | CYP4F2CYP4A11GABRA2GABRB2 | |
| SCHEMBL25734935 | 0.77 | GABRA2 (0.32) | GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | CYP4F2 3314/4885CYP4A11 4275/4885GABRA2 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.